{"id":"W2898547742","doi":"10.1093/annonc/mdy289","title":"KEYNOTE-022 Part 3: Phase II randomized study of 1L dabrafenib (D) and trametinib (T) plus pembrolizumab (Pembro) or placebo (PBO) for BRAF-mutant advanced melanoma","year":2018,"lang":"fr","type":"article","venue":"Annals of Oncology","topic":"Melanoma and MAPK Pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":50,"is_retracted":false,"has_abstract":true,"ca_institutions":"Université Laval; Centre hospitalier universitaire de Québec","funders":"","keywords":"Dabrafenib; Medicine; Tolerability; Discontinuation; Pembrolizumab; Internal medicine; Placebo; Clinical endpoint; Gastroenterology; Nuclear medicine; Clinical trial; Adverse effect; Metastatic melanoma; Immunotherapy; Cancer; Pathology; Vemurafenib","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0018821,0.0005728352,0.002303292,0.0001701499,0.0002560677,0.00001665011,0.000466018,0.0007602309,0.0003411524],"category_scores_gemma":[0.001572074,0.0004940633,0.0004420355,0.0001975328,0.001369562,0.00002439548,0.0003785494,0.0002200216,0.000005930903],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00003275315,"about_ca_system_score_gemma":0.0009498362,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001140256,"about_ca_topic_score_gemma":0.0005539124,"domain_scores_codex":[0.9952402,0.001073172,0.001606831,0.0009708226,0.0002540181,0.0008550024],"domain_scores_gemma":[0.9962358,0.0007499072,0.00116096,0.0007719002,0.0007632609,0.0003181311],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.6198724,0.00822306,0.00002510867,0.0004917526,0.001592383,0.0000750516,0.003672162,0.00002385546,0.2123288,0.001112712,0.0071152,0.1454675],"study_design_scores_gemma":[0.3980518,0.1145643,0.00001762565,0.00009320642,0.0005174318,0.0001486654,0.001326051,0.0004172758,0.2319034,0.0002947089,0.2521972,0.0004683986],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9817339,0.006978972,0.000916814,0.001426247,0.001572905,0.003933257,0.0005692324,0.00001753055,0.002851126],"genre_scores_gemma":[0.9905027,0.002545307,0.00151476,0.0005659729,0.000819858,0.000446143,0.0001602352,0.00007150314,0.003373486],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.245082,"threshold_uncertainty_score":0.9997511,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0654847845609551,"score_gpt":0.3826286166165271,"score_spread":0.317143832055572,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}